Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib

The Bruton tyrosine kinase (BTK) inhibitor ibrutinib has excellent clinical activity in patients with chronic lymphocytic leukemia (CLL). Characteristically, ibrutinib causes CLL cell redistribution from tissue sites into the peripheral blood during the initial weeks of therapy. To better characteri...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Wodarz, Dominik, Garg, Naveen, Komarova, Natalia L., Benjamini, Ohad, Keating, Michael J., Wierda, William G., Kantarjian, Hagop, James, Danelle, O’Brien, Susan, Burger, Jan A.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2014
Teme:
Lymphoid Neoplasia
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123432/
https://ncbi.nlm.nih.gov/pubmed/24829205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-02-554220
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items